Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

81. Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer — Details

Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer — Details Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer — Details | CADTH.ca Find the information you need Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer — Details Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer — Details Project Number pCODR 10197 Brand Name Lonsurf Generic Name Trifluridine-Tipiracil Tumour Type Gastrointestinal Indication Gastric Cancer Funding Request For the treatment of adult patients with metastatic (...) gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease Review Status Under Review Pre Noc Submission Yes NOC Date Manufacturer Taiho Pharma Canada, Inc. Sponsor Taiho Pharma Canada, Inc. Submission Date September 3, 2019 Submission Deemed Complete September 17, 2019 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ September 17, 2019 Check

2019 CADTH - Pan Canadian Oncology Drug Review

82. Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details

Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details | CADTH.ca Find the information you need Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details Project Number pCODR 10171 Brand Name Tecentriq Generic Name Atezolizumab Strength 840 mg (...) /14 mL & 1200 mg/20 mL Tumour Type Breast Indication Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Funding Request In combination with nab-paclitaxel for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours express PD-L1, and who have not received prior chemotherapy for metastatic disease. Maintenance TECENTRIQ should be continued until disease progression or unacceptable toxicity. Review Status Open

2019 CADTH - Pan Canadian Oncology Drug Review

83. Nerlynx for Hormone Receptor-Positive Breast Cancer – Details

Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details | CADTH.ca Find the information you need Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Nerlynx for Hormone Receptor-Positive Breast Cancer – Details Project Number pCODR 10172 Brand Name Nerlynx Generic Name Neratinib Strength 40 mg Tumour Type Breast Indication Hormone Receptor-Positive Breast Cancer Funding Request For patients with HER2-positive, hormone (...) receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months Review Status Open for Feedback on Recommendation Pre Noc Submission Yes NOC Date July 16, 2019 Manufacturer Knight Therapeutics Inc. Sponsor Knight Therapeutics Inc. Submission Date April 18, 2019 Submission Deemed Complete May 3, 2019 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ May 3, 2019 Check-point meeting July 4, 2019 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

84. Tecentriq for Small Cell Lung Cancer – Details

Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Tecentriq for Small Cell Lung Cancer – Details Tecentriq for Small Cell Lung Cancer – Details Project Number pCODR 10156 Brand Name Tecentriq Generic Name Atezolizumab Strength 60 mg/mL Tumour Type Lung Indication Small Cell Lung Cancer (SCLC) Funding Request For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC

2019 CADTH - Pan Canadian Oncology Drug Review

85. Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details

Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details | CADTH.ca Find the information you need Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Abiraterone (Zytiga) for Prostate Cancer Resubmission - Details Project Number pCODR 10201 Brand Name Zytiga (Resubmission) Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed high (...) -risk metastatic castration sensitive prostate cancer without small-cell histologic features. Patients required to have at least two of the three following high-risk factors: Gleason score of 8 or more, at least 3 bone lesions, and presence of visceral metastasis. Less than 3 months of androgen deprivation therapy (or orchiectomy) for metastatic disease. Eligible for abiraterone therapy. Review Status Under Review Pre Noc Submission No NOC Date February 15, 2018 Manufacturer Janssen Inc. Sponsor BC

2019 CADTH - Pan Canadian Oncology Drug Review

86. Lynparza for Newly Diagnosed Ovarian Cancer – Details

Lynparza for Newly Diagnosed Ovarian Cancer – Details Lynparza for Newly Diagnosed Ovarian Cancer – Details | CADTH.ca Find the information you need Lynparza for Newly Diagnosed Ovarian Cancer – Details Lynparza for Newly Diagnosed Ovarian Cancer – Details Project Number pCODR 10174 Brand Name Lynparza Generic Name Olaparib Strength 100 mg and 150 mg Tumour Type Gynecology Indication Ovarian Cancer Funding Request As monotherapy for the maintenance treatment of adult patients with newly (...) diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy, until disease progression or up to 2 years if no evidence of disease. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated. Review Status Open for Feedback on Recommendation Pre Noc Submission Yes NOC Date May 6

2019 CADTH - Pan Canadian Oncology Drug Review

87. Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details

Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details | CADTH.ca Find the information you need Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Xtandi for non-metastatic Castration-Resistant Prostate Cancer – Details Project Number pCODR 10149 Brand Name Xtandi Generic Name Enzalutamide Strength 40 mg Tumour Type Genitourinary Indication Non-metastatic castration-resistant (...) prostate cancer Funding Request High risk, non-metastatic castration-resistant prostate cancer Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date December 20, 2018 Manufacturer Astellas Pharma Canada, Inc. Sponsor Astellas Pharma Canada, Inc. Submission Date September 24, 2018 Submission Deemed Complete October 9, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ October 9, 2018 Check-point meeting November 20, 2018 pERC Meeting

2019 CADTH - Pan Canadian Oncology Drug Review

88. Zytiga for Prostate Cancer – Details

Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details | CADTH.ca Find the information you need Zytiga for Prostate Cancer – Details Zytiga for Prostate Cancer – Details Project Number pCODR 10166 Brand Name Zytiga Generic Name Abiraterone Strength 250 mg & 500 mg Tumour Type Genitourinary Indication Prostate Cancer Funding Request Newly diagnosed with metastatic prostate cancer without small-cell histologic features (may have received prior surgery or radiation therapy (...) for local disease or palliative therapy); Less than 3 months of androgen deprivation therapy for metastatic disease (may have received prior adjuvant/neoadjuvant hormone therapy); Eligible for abiraterone therapy Review Status Withdrawn Clarification BC Cancer Agency has requested a voluntary withdrawal of the pCODR 10166 Abiraterone (Zytiga) for PC Submission. As per pCODR Procedures B3.1.6.2 b), the pCODR Provincial Advisory Group has agreed to the request to withdraw and decided to not continue

2019 CADTH - Pan Canadian Oncology Drug Review

89. Imfinzi for Non-Small Cell Lung Cancer – Details

Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Imfinzi for Non-Small Cell Lung Cancer – Details Imfinzi for Non-Small Cell Lung Cancer – Details Project Number pCODR 10131 Brand Name Imfinzi Generic Name Durvalumab Strength 50 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the treatment of patients with locally advanced, unresectable non-small cell lung cancer (NSCLC

2019 CADTH - Pan Canadian Oncology Drug Review

90. Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details

Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details | CADTH.ca Find the information you need Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Ibrance (with Faslodex) for Advanced or Metastatic Breast Cancer – Details Project Number pCODR 10150 Brand Name Ibrance (with Faslodex) Generic Name Palbociclib (with Fulvestrant) Strength 75 mg, 100 mg & 125 mg Tumour Type Breast (...) Indication Advanced or Metastatic Breast Cancer Funding Request In combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy, Pre- or perimenopausal women must also be treated with a luteinizing hormone releasing hormone (LHRH) agonist Review Status Notification to Implement Issued Pre Noc Submission No NOC Date May

2019 CADTH - Pan Canadian Oncology Drug Review

91. Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details

Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Ogivri for Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar – Details Project Number pCODR 10169 (...) Brand Name Ogivri Generic Name Trastuzumab Strength 150 mg/vial and 440 mg/vial Tumour Type Breast / Gastrointestinal Indication Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar Funding Request For the treatment of patients with early stage breast cancer with ECOG 0-1 status, whose tumours overexpress HER2, following surgery and after chemotherapy, following adjuvant chemotherapy consisting of doxorubicin and cyclophosphamide, in combination with paclitaxel

2019 CADTH - Pan Canadian Oncology Drug Review

92. Trastuzumab for Breast and Gastric Cancer Biosimilar – Details

Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details | CADTH.ca Find the information you need Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Trastuzumab for Breast and Gastric Cancer Biosimilar – Details Project Number pCODR 10160 Brand Name TBD Generic Name Trastuzumab Strength Tumour Type Breast & Gastrointestinal Indication Breast and Gastric Cancer Biosimilar Funding Request Breast and Gastric Cancer

2019 CADTH - Pan Canadian Oncology Drug Review

93. Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details

Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Xalkori for ROS1-positive advanced Non-Small Cell Lung Cancer – Details Project Number pCODR 10151 Brand Name Xalkori Generic Name Crizotinib Strength 200 mg & 250 mg Tumour Type Lung Indication ROS1-positive advanced Non-Small Cell Lung (...) Cancer Funding Request As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC) Review Status Notification to Implement Issued Pre Noc Submission No NOC Date August 28, 2017 Manufacturer Pfizer Canada Inc. Sponsor Cancer Care Ontario Lung Cancer Drug Advisory Committee Submission Date October 30, 2018 Submission Deemed Complete November 13, 2018 Submission Type New Indication Prioritization Requested Stakeholder Input Deadline ‡ November 13

2019 CADTH - Pan Canadian Oncology Drug Review

94. Vizimpro for Non-Small Cell Lung Cancer – Details

Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details | CADTH.ca Find the information you need Vizimpro for Non-Small Cell Lung Cancer – Details Vizimpro for Non-Small Cell Lung Cancer – Details Project Number pCODR 10129 Brand Name Vizimpro Generic Name Dacomitinib Strength 15 mg, 30 mg & 45 mg Tumour Type Lung Indication Non-Small Cell Lung Cancer Funding Request For the first-line treatment of patients with locally advanced or metastatic non (...) ‑small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. Review Status Notification to Implement Issued Pre Noc Submission Yes NOC Date February 26, 2019 Manufacturer Pfizer Canada Inc. Sponsor Pfizer Canada Inc. Submission Date September 19, 2018 Submission Deemed Complete October 3, 2018 Submission Type New Drug Prioritization Requested Stakeholder Input Deadline ‡ October 3, 2018 Check-point meeting December 4, 2018 pERC Meeting March 21, 2019 Initial

2019 CADTH - Pan Canadian Oncology Drug Review

95. Abemaciclib for advanced or metastatic Breast Cancer – Details

Abemaciclib for advanced or metastatic Breast Cancer – Details Abemaciclib for advanced or metastatic Breast Cancer – Details | CADTH.ca Find the information you need Abemaciclib for advanced or metastatic Breast Cancer – Details Abemaciclib for advanced or metastatic Breast Cancer – Details Project Number pCODR 10161 Brand Name Verzenio Generic Name Abemaciclib Strength 50 mg, 100 mg, 150 mg and 200 mg Tumour Type Breast Indication Advanced or metastatic breast cancer Funding Request (...) For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer: • In combination with an aromatase inhibitor in postmenopausal women as initial endocrine based therapy. • In combination with fulvestrant in women with disease progression following endocrine therapy. Pre- or perimenopausal women must also be treated with a gonadotropin-releasing hormone agonist. Review Status Notification to Implement Issued Pre Noc Submission Yes

2019 CADTH - Pan Canadian Oncology Drug Review

96. Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT

Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT Robotic-assisted surgery compared with laparoscopic resection surgery for rectal cancer: the ROLARR RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need (...) . >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} There is insufficient evidence to conclude that robotic rectal cancer surgery compared with laparoscopic surgery reduces the risk of conversion to laparotomy, and overall it results in comparable outcomes and it was more expensive. {{author}} {{($index , , , , , , , , , & . David Jayne 1, * , Alessio Pigazzi 2 , Helen Marshall 3 , Julie Croft 3 , Neil Corrigan 3 , Joanne Copeland 3 , Philip Quirke 4 , Nicholas

2019 NIHR HTA programme

97. The Impact of Adverse Childhood Experiences on the Utilization of Cervical Cancer Screening

The Impact of Adverse Childhood Experiences on the Utilization of Cervical Cancer Screening "The Impact of Adverse Childhood Experiences on the Utilization of Cerv" by Jennifer Mings < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Abstract Background: Adverse childhood experiences (ACEs) are prevalent for many women, and have been proven to lead to an increase in chronic (...) diseases including cancer. While the mechanism behind this is not completely understood, the literature suggests that it may be partially due to decreased utilization of cancer screening. Due to the widespread nature of cervical cancer, this literature review seeks to investigate the relationship between ACEs and cervical cancer screening. Methods: An exhaustive literature search of MEDLINE-PubMed, Web of Science, Public Health Database, and PyschINFO was performed. The keywords used in the search

2019 Pacific University EBM Capstone Project

98. The Effects of a Plant-Based Diet and Stress Reduction Techniques on PSA Doubling Time in Prostate Cancer Recurrence

The Effects of a Plant-Based Diet and Stress Reduction Techniques on PSA Doubling Time in Prostate Cancer Recurrence "The Effects of a Plant-Based Diet and Stress Reduction Techniques on P" by Amanda Barclay and Jacob McAvoy < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Prostate cancer is the most common cancer affecting men. It is also very common for men (...) to suffer from recurrence after primary therapy is completed. The current most commonly used therapies for prostate cancer recurrence, hormonal therapy and radiation, have significant side effects. It is known that diet influences cancer prevention, progression, and recurrence. A plant-based diet, especially when combined with stress reduction techniques, may be a useful therapeutic option with fewer side effects for men with recurrent prostate cancer. This review examines the effects of a plant-based

2019 Pacific University EBM Capstone Project

99. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease

Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01696 Journal of Clinical Oncology - published online before print September 18, 2019 PMID: Management (...) of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline , MD 1 x Charles L. Shapiro ; , MD 2 x Catherine Van Poznak ; , MHSc 3 x Christina Lacchetti ; , MD 4 x Jeffrey Kirshner ; , MD 5 x Richard Eastell ; , MD 6 x Robert Gagel ; , MD 2 x Sean Smith ; , MD, MPH 7 x Beatrice J. Edwards ; , EdM 8 x Elizabeth Frank ; , MD, MPH 9 x Gary H. Lyman ; , MD, PhD 10 x Matthew R. Smith ; , PhD, MPH 11 x Rahul Mhaskar ; , MD, MPH 12 x Tara Henderson ; and , MD, MPH 13 x

2019 American Society of Clinical Oncology Guidelines

100. Use of Endocrine Therapy for Breast Cancer Risk Reduction

Use of Endocrine Therapy for Breast Cancer Risk Reduction Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01472 Journal of Clinical Oncology - published online before print September 3, 2019 PMID: Use of Endocrine Therapy for Breast Cancer Risk Reduction (...) of Medicine and Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 2 University of Kansas Medical Center, Kansas City, KS 3 Johns Hopkins School of Medicine, Baltimore, MD 4 University of Texas MD Anderson Cancer Center, Houston, TX 5 University of Washington, Seattle, WA 6 National Hospital E.O. Ospedali Galliera S.C. Oncologia Medica, Genoa, Italy; and Queen Mary University of London, United Kingdom 7 Cancer Care Specialists of Illinois, Swansea, IL 8 Dana-Farber Cancer Institute, Boston, MA

2019 American Society of Clinical Oncology Guidelines